A Phase Ia/Ib Study of the Safety and Immunogenicity of a Xenogeneic Tyrosinase DNA Vaccine Melanoma.

Trial Profile

A Phase Ia/Ib Study of the Safety and Immunogenicity of a Xenogeneic Tyrosinase DNA Vaccine Melanoma.

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 03 Jun 2011

At a glance

  • Drugs Tyrosinase DNA vaccine (Primary)
  • Indications Malignant melanoma
  • Focus Adverse reactions
  • Sponsors Ichor Medical Systems
  • Most Recent Events

    • 09 Jun 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 05 Mar 2008 Recruitment into the highest dose level has commenced, according to a Ichor Medical Systems media release.
    • 23 Mar 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top